value (generated by 1 mg · h/ml from 8 to 43 mg · h/ml) in receiver operating characteristic (ROC) curve analysis. At each cutoff AUC 0-∞ value, sensitivity, specificity, and positive and negative likelihood ratios were calculated. The cutoff AUC 0-∞ value for adverse events was determined by drawing the ROC curve. Correlations between AUC 0-∞ and plasma concentration at each time point (1, 2, 4, 6, 8, 12 , 24 h) after the first and second administration were evaluated by simple linear regression analysis. Pharmacokinetics The plasma concentration-time profiles after the first and second administration at a dose of 100 mg were well fitted to the simulation curves (Fig. 1) . The pharmacokinetic parameters are summarized in Table 1 . Each parameter was not significantly different between the first and second administration.
RESULTS

Demographics
Dosage and Adverse Events
The dosage and adverse events were classified into three patterns (Table 2 ). In the first pattern, patients A and C suffered Grade 2 adverse events and patient B complained leg edema at a dose of 100 mg, and the dosing rate was reduced and discontinued within 4 weeks. In the second pattern, with the dose increased to 200 mg, patient D suffered Grade 3 adverse events and the drug was discontinued. Patients E and F complained various Grade 1 adverse events, then the dosing rate was decreased, and was finally discontinued within 12 weeks. In the third pattern, adverse events did not occur at a dose of 200 mg. Patient H was maintained at 200 mg for more than a year, although patient G withdrew informed consent and discontinued the treatment on Day 44.
Relationship between Adverse Events, AUC and Plasma Concentrations Analyzing the data sets of adverse events (presence, patients A, B and C; absence, the other patients) and AUC 0-∞ after the first and second 100 mg administration, the ROC curve indicated that adverse events were associated with the AUC 0-∞ of thalidomide: the cutoff AUC 0-∞ value for adverse events was 23 and 24 mg · h/ml, and the sensitivity, 1-specificity, positive likelihood ratio and negative likelihood ratio were 0.83, 0.1, 8.3 and 0.19, respectively (Fig. 2) .
The best correlation was observed between AUC 0-∞ and plasma concentration at 12 h (C 12 ) after both the first and second administration alike, though the mean intra-individual variation ([C 12 (2nd) ϪC 12 (1st) ]/C 12 (1st) ϫ100) was 30.6%. With this correlation, 23-24 mg · h/ml of AUC 0-∞ was estimated to be relevant to 0.85-0.89 and 1.03-1.09 mg /ml of C 12 after the first and second administration, respectively (Fig. 3) .
DISCUSSION
This study was a full sampling design to examine the pharmacokinetics precisely in Japanese patients with multiple myeloma. The mean values of the volume of distribution including the fraction of absorbed dose (Vd/F ), the total clearance including the fraction of absorbed dose (CL/F ) and the elimination half-life (T 1/2 ) were 42.2-47.1 l, 5.44-5.54 l/h and 5.71-6.32 h, respectively (Table 1) , and Vd/F and CL/F were smaller than those reported previously: Teo et al. 10) found that the averages of Vd/F , CL/F and T 1/2 were 94.0 l, 11.1 l/h and 5.75 h, respectively, after 200 mg dosing to healthy male subjects. Piscitelli et al. 11) demonstrated that the averages of Vd/F , CL/F and T 1/2 were 87.8 l, 9.2 l/h and 6.5 h, respectively, after 100 mg dosing to human immunodeficiency virus-infected patients. Thalidomide pharmacokinetics are evaluated to be similar between healthy and patient populations, 12) and we speculated that the smaller Vd/F and CL/F may result from differences other than diseases, for example, lower body weight or higher bioavailability in Japanese patients. Consequently, AUC 0-∞ was 22.6Ϯ10.9 and 21.0Ϯ8.58 mg · h/ml after the first and second 100 mg administration, respectively (Table 1) . This was comparable to 20.9Ϯ6.7 mg · h/ml after 200 mg dosing to five New Zealand patients with refractory multiple myeloma. 13) We considered that this pharmacokinetic difference may explain the dose difference for the treatment of refractory multiple myeloma.
ROC curve analysis 14, 15) was performed to examine the relationship between adverse events and AUC 0-∞ . ROC curve is a graphical plot of the sensitivity versus 1-specificity for a binary classifier system as its discrimination threshold is varied. The best possible prediction method would yield a graph that is a point in the upper left corner of the ROC space. As shown in Fig. 2 , AUC 0-∞ was associated with adverse events of thalidomide and the cutoff AUC 0-∞ value for adverse events was 23-24 mg · h/ml. Although we did not evaluate AUC 0-∞ at a dose of 200 mg, we expect that AUC 0-∞ at a dose of 200 mg may be double that at a dose of 100 mg, taking into consideration that AUC 0-∞ increased proportionally with doses from 50 to 400 mg in healthy male subjects. 16) Thus, we speculated that, at 200 mg dosing, patients D, E and F suffered adverse events because their AUC 0-∞ was above 23-24 mg · h/ml, while patients G and H did not suffer adverse events because their AUC 0-∞ was approximately equal or below the cutoff value (Table 2) .
Previous researches 4, 17) examined the relationship between the plasma concentrations of thalidomide and the drug response in Japanese patients with multiple myeloma, and demonstrated that thalidomide-related toxicity except neutropenia occurred more frequently with higher plasma levels (C 12 Ͼ2.0 mg /ml). The present study also suggested that it was important to monitor C 12 for safety reason, however, its cutoff value was lower (1 mg /ml). We considered this discrepancy was because our analyses placed the highest prior- Acute bronchitis ity on avoiding adverse events to continue the treatment. As well as previous studies, 10, 16) this study was conducted in daytime although thalidomide is usually administered before bedtime. In the approved protocol, we gave priority to frequent full sampling on the initial two days, and were unable to obtain samples another time due to reducing the burden of excessive sampling for patients. Gastric emptying rate, intestinal blood flow rate and peristaltic activity could differ between day and night, we did not examine the influence of administration time on the pharmacokinetics of thalidomide. Further pharmacokinetic research to collect the steady-state plasma samples after nighttime administration, especially C 12 in the morning, is needed to confirm whether 1 mg /ml is appropriate as a target value for "safety-oriented" therapeutic drug monitoring of thalidomide to avoid adverse events and continue the treatment.
